Topic

J&J

A collection of 2 issues

J&J Shares Climb 2% After Key Announcement

J&J's shares increased by 2% post-announcement, while AstraZeneca's remained stable. Discover what fueled this stock movement and market reaction.

J&J's Treatment Boosts Survival for Lung Cancer Patients Over Tagrisso

Johnson & Johnson's new therapy significantly extends survival in non-small cell lung cancer patients, outperforming AstraZeneca's Tagrisso by over a year.